RxDoctor Payments Data

Mary Rose Fabi, MD

Internal Medicine · Oakland, CANPI 1740489798

Payments from drug & device makers

$360in general payments, 2019–2025

Across 9 payments — averaging $39.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$122
  • Boston Scientific$122
  • AstraZeneca$55
  • Abbott$24
  • AbbVie$22
  • Sanofi Pasteur Inc.$15

What the payments were for

  • Food & beverage$360100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Coloplast2$122
Boston Scientific2$122
AstraZeneca2$55
Abbott1$24
AbbVie1$22
Sanofi Pasteur Inc.1$15

How this compares

$360 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$292,820
Medicare patients
689
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$90,298
FarxigaDapagliflozin Propanediol52$49,797
XareltoRivaroxaban31$33,289
OzempicSemaglutide12$11,437
SymbicortBudesonide/Formoterol Fumarate34$10,979
JardianceEmpagliflozin12$10,695
Spiriva RespimatTiotropium Bromide18$9,258
NamzaricMemantine Hcl/Donepezil Hcl12$8,230
Atorvastatin Calcium546$5,718
Levothyroxine Sodium316$4,224
Gabapentin184$3,759
Albuterol Sulfate HfaAlbuterol Sulfate141$3,295
SynthroidLevothyroxine Sodium48$3,024
Metoprolol Succinate176$2,574
Escitalopram Oxalate125$2,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$55$60,77586 claims
AbbVieNamzaric, Synthroid$22$11,25460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oakland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →